Ahmad Al-Hader
Overview
Explore the profile of Ahmad Al-Hader including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
62
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nassar A, Abou Alaiwi S, El Zarif T, Denu R, Macaron W, Abdel-Wahab N, et al.
J Immunother Cancer
. 2025 Mar;
13(3).
PMID: 40032601
Background: Data on the safety profiles and clinical outcomes of patients with solid tumors and cardiac metastasis treated with immune checkpoint inhibitors (ICIs) are limited. Methods: This is an international...
2.
Nassar A, El-Am E, Denu R, Abou Alaiwi S, El Zarif T, Macaron W, et al.
JACC CardioOncol
. 2024 Mar;
6(1):71-79.
PMID: 38510282
Background: Primary cardiac soft tissue sarcomas (CSTS) affect young adults, with dismal outcomes. Objectives: The aim of this study was to investigate the clinical outcomes of patients with CSTS receiving...
3.
Nassar A, El Zarif T, Khalid A, Rahme S, Zhong C, Kwak L, et al.
J Immunother Cancer
. 2024 Mar;
12(3).
PMID: 38448038
Background: Patients with paraneoplastic syndromes (PNS) are excluded from clinical trials involving immune checkpoint inhibitors (ICIs) due to safety concerns. Moreover, real-world data on efficacy and safety is scarce. Methods:...
4.
Duncan F, Al Nasrallah N, Nephew L, Han Y, Killion A, Liu H, et al.
Transl Lung Cancer Res
. 2024 Feb;
13(1):76-94.
PMID: 38405005
Background: Black race is associated with advanced stage at diagnosis and increased mortality in non-small cell lung cancer (NSCLC). Most studies focus on race alone, without accounting for social determinants...
5.
El Zarif T, Nassar A, Adib E, Fitzgerald B, Huang J, Mouhieddine T, et al.
J Clin Oncol
. 2023 May;
41(21):3712-3723.
PMID: 37192435
Purpose: Compared with people living without HIV (PWOH), people living with HIV (PWH) and cancer have traditionally been excluded from immune checkpoint inhibitor (ICI) trials. Furthermore, there is a paucity...
6.
Lin I, Shotts M, Al-Hader A, Jones Weddle K, Holden R, Mueller E, et al.
PLoS One
. 2022 Sep;
17(9):e0274963.
PMID: 36137161
Background: The number of oral anticancer medications has increased over the past few decades, opening new possibilities in cancer care and improving convenience for patients and caregivers. However, adherence levels...
7.
Miller C, Al-Hader A, Vance G, Zhang C
BMJ Case Rep
. 2022 Jul;
15(7).
PMID: 35858740
Malignant gastrointestinal neuroectodermal tumour (GNET) is a rare, aggressive neoplasm with fewer than 100 cases reported in the literature. Most cases arise in the tubular gastrointestinal tract. We reported a...
8.
Pettit N, Al-Hader A
Acad Emerg Med
. 2021 Nov;
29(4):500-502.
PMID: 34797610
No abstract available.
9.
Al Nasrallah N, Al-Hader A, Samala N, Sears C
Crit Care Explor
. 2021 Jan;
3(1):e0318.
PMID: 33458685
Design: Retrospective observational study. Setting: Tertiary-care medical ICU. Patients: Thirty-one patients critically ill with hemophagocytic lymphohistiocytosis. Interventions: None. Measurements And Main Results: We performed a comprehensive review of critically ill...
10.
Pettit N, Al-Hader A
J Am Coll Emerg Physicians Open
. 2020 Aug;
1(4):669.
PMID: 32838377
No abstract available.